A study analyzing millions of Food and Drug Administration adverse event reports identifies Wegovy as carrying the highest reported risk among GLP-1 drugs for a rare eye stroke condition that can cause sudden vision loss, according to research published in May 2026.
Investigators mined the FDA’s public FAERS database using disproportionality analysis to detect ocular ischemic events reported more frequently among semaglutide brand users relative to other weight-loss medications in the same class.
Non-arteritic anterior ischemic optic neuropathy remains uncommon, but vision-threatening outcomes warrant clinician awareness when patients report acute visual changes after initiating or escalating doses. Causality cannot be proven from spontaneous reports alone because confounding comorbidities and reporting bias influence database signals.
Novo Nordisk said labeled safety information continues to evolve with post-marketing surveillance and that clinical trials did not show significant optic nerve event imbalances relative to controls. Ophthalmologists advised urgent evaluation for sudden painless vision loss regardless of medication status.
The findings arrive amid soaring Wegovy prescriptions and telehealth prescribing debates. Regulatory agencies may request additional epidemiological studies using insurance claims rather than voluntary reporting systems.
Patients should not discontinue prescribed therapy without medical consultation based solely on database analyses.
Eye specialists said anyone experiencing sudden painless vision changes should seek emergency evaluation regardless of whether they use GLP-1 medications or other systemic therapies.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/